West Pharmaceutical Services, Inc.
WST Healthcare Medical Instruments & Supplies
West Pharmaceutical Services, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.1 billion, up 6.25% from fiscal 2024. In the quarter to June 2026, revenue grew 13.8%, EPS grew 19.2%, free cash flow fell 20.7% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.
Follow WST
West Pharmaceutical Services, Inc. (WST) P/S ratio
As of 16 October 2026, West Pharmaceutical Services, Inc. (WST) trades at a P/S ratio of 8.1×. Over the past ten years it has ranged from 2.5× (February 2015) to 13.7× (September 2021); the current reading is higher than 70% of that period. That is above the Medical Instruments & Supplies industry median of 2.5× and above the Healthcare sector median of 3.4×.
P/S ratio, daily
Embed this chart
Annual newest first
| Period | P/S ratio | Change |
|---|---|---|
| FY2025 | 6.5× | (21.71%) |
| FY2024 | 8.3× | (5.90%) |
| FY2023 | 8.8× | 45.39% |
| FY2022 | 6.0× | (50.98%) |
| FY2021 | 12.3× | 26.37% |
| FY2020 | 9.8× | 61.29% |
| FY2019 | 6.0× | 43.34% |
| FY2018 | 4.2× | (8.26%) |
| FY2017 | 4.6× | 12.61% |
| FY2016 | 4.1× | 31.83% |
Quarterly newest first
| Period | P/S ratio | Change |
|---|---|---|
| Jun 2026 | 7.6× | 36.37% |
| Mar 2026 | 5.6× | (13.42%) |
| Dec 2025 | 6.5× | 3.11% |
| Sep 2025 | 6.3× | 17.60% |
| 42 more quarters | Free account |
Against its own ten years
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| MDLN Medline Inc. compare | 1.0× |
| BAX Baxter International Inc. compare | 1.1× |
| SOLV Solventum Corporation compare | 1.8× |
| BDX Becton, Dickinson and Company compare | 2.4× |
| COO The Cooper Companies, Inc. compare | 2.6× |
| ALC Alcon compare | 3.0× |
| RMD ResMed Inc. compare | 6.2× |
| WST West Pharmaceutical Services, Inc. | 8.1× |
| RGEN Repligen Corporation compare | 12.6× |
| Medical Instruments & Supplies industry median | 2.5× |
| Healthcare sector median | 3.4× |
| Market median | 1.9× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on WST
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement